| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Bing Li | |
| Donald T Moir | |||
| Norton P Peet | |||
| Terry L Bowlin | |||
| Michelle M Butler | |||
| James C Burnett | |||
| P2860 | cites work | Pharmacophore-guided lead optimization: the rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype a metalloprotease | Q84458383 |
| Substrate recognition strategy for botulinum neurotoxin serotype A. | Q46801352 | ||
| Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity | Q46895651 | ||
| Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity | Q47852269 | ||
| Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin | Q48268335 | ||
| Lectins from Triticum vulgaris and Limax flavus are universal antagonists of botulinum neurotoxin and tetanus toxin | Q48669080 | ||
| Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxins | Q49164892 | ||
| Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. | Q52099909 | ||
| Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation | Q58120767 | ||
| The effect of toosendanin on monkey botulism | Q69821848 | ||
| Ammonium chloride and methylamine hydrochloride antagonize clostridial neurotoxins | Q71769975 | ||
| Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins | Q72389951 | ||
| Dichain structure of botulinum neurotoxin: identification of cleavage sites in types C, D, and F neurotoxin molecules | Q73854154 | ||
| Intimate details of the most poisonous poison | Q74133716 | ||
| A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease | Q80119496 | ||
| Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design | Q81130685 | ||
| Botulinal neurotoxins: revival of an old killer | Q23832313 | ||
| Botulinum Toxin as a Biological Weapon: Medical and Public Health Management | Q23832736 | ||
| Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution | Q27626210 | ||
| Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B | Q27626220 | ||
| A novel mechanism for Clostridium botulinum neurotoxin inhibition | Q27639431 | ||
| Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility | Q27644919 | ||
| Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex | Q27650538 | ||
| A Potent Peptidomimetic Inhibitor of Botulinum Neurotoxin Serotype A Has a Very Different Conformation than SNAP-25 Substrate | Q27652600 | ||
| Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation | Q27653311 | ||
| Crystal structure of botulinum neurotoxin type A and implications for toxicity | Q27765727 | ||
| Botulinum and tetanus neurotoxins: structure, function and therapeutic utility | Q28609172 | ||
| Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin | Q28609203 | ||
| Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala peptide bond | Q28609204 | ||
| Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E | Q28609206 | ||
| Proteolysis of SNAP-25 by types E and A botulinal neurotoxins | Q28609208 | ||
| Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design | Q28750297 | ||
| Small molecules showing significant protection of mice against botulinum neurotoxin serotype A | Q28752594 | ||
| Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin | Q29619130 | ||
| Novel Benzimidazole Inhibitors of Botulinum Neurotoxin/A Display Enzyme and Cell-Based Potency | Q30423794 | ||
| Benzylidene cyclopentenediones: First irreversible inhibitors against botulinum neurotoxin A's zinc endopeptidase | Q33637465 | ||
| Toosendanin: synthesis of the AB-ring and investigations of its anti-botulinum properties (Part II). | Q33643294 | ||
| Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease | Q33651107 | ||
| Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors | Q33703468 | ||
| Light Chain Separated from the Rest of the Type A Botulinum Neurotoxin Molecule Is the Most Catalytically Active Form | Q33705121 | ||
| Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease | Q33722985 | ||
| Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors | Q33739700 | ||
| Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody | Q34038244 | ||
| Development of vaccines for prevention of botulism | Q34086666 | ||
| Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons | Q34154552 | ||
| Pharmacophore Refinement Guides the Rational Design of Nanomolar-Range Inhibitors of the Botulinum Neurotoxin Serotype A Metalloprotease | Q34353299 | ||
| Clostridium botulinum: a bug with beauty and weapon | Q34412430 | ||
| Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases | Q34444412 | ||
| Biological and chemical agents: a brief synopsis | Q34488054 | ||
| Microbiological, biological, and chemical weapons of warfare and terrorism | Q34695957 | ||
| Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes | Q35060579 | ||
| Therapy and prophylaxis of inhaled biological toxins | Q35148875 | ||
| The zinc-dependent protease activity of the botulinum neurotoxins | Q35155792 | ||
| Identification of the major steps in botulinum toxin action | Q35639122 | ||
| Botulin toxin: a weapon in terrorism | Q35686984 | ||
| Botulinum toxins in neurological disease | Q35759634 | ||
| Cure of experimental botulism and antibotulismic effect of toosendanin. | Q35787858 | ||
| Progress toward development of an inhalation vaccine against botulinum toxin | Q35843653 | ||
| Medical aspects of biologic toxins | Q35869555 | ||
| The medicinal chemistry of botulinum, ricin and anthrax toxins | Q36079816 | ||
| The evolving field of biodefence: therapeutic developments and diagnostics | Q36085668 | ||
| Bacteria as potential tools in bioterrorism, with an emphasis on bacterial toxins | Q36091510 | ||
| A new wrinkle on pain relief: re-engineering clostridial neurotoxins for analgesics | Q36101373 | ||
| Expanding use of botulinum toxin. | Q36180106 | ||
| Medical aspects of toxin weapons. | Q36222475 | ||
| Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells | Q36325534 | ||
| Biological effects of toosendanin, a triterpenoid extracted from Chinese traditional medicine | Q36760794 | ||
| Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition | Q36973191 | ||
| Function-oriented synthesis, step economy, and drug design | Q37045266 | ||
| Bimodal modulation of the botulinum neurotoxin protein-conducting channel | Q37083575 | ||
| Function-oriented synthesis applied to the anti-botulinum natural product toosendanin | Q37141890 | ||
| Botulinum neurotoxin serotype A inhibitors: small-molecule mercaptoacetamide analogs. | Q37181870 | ||
| Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A | Q37274652 | ||
| The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison | Q37289989 | ||
| Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. | Q39742947 | ||
| Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding. | Q40461076 | ||
| Structure and function of tetanus and botulinum neurotoxins. | Q41082871 | ||
| The interaction between aminoquinolines and presynaptically acting neurotoxins | Q41923024 | ||
| Novel 4-aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A. | Q41940551 | ||
| Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons | Q42602928 | ||
| Quinolinol and peptide inhibitors of zinc protease in botulinum neurotoxin A: effects of zinc ion and peptides on inhibition | Q43272967 | ||
| Proteolysis of synthetic peptides by type A botulinum neurotoxin | Q44592997 | ||
| Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. | Q44881077 | ||
| Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Glu212-->Gln reveals the pivotal role of the Glu212 carboxylate in the catalytic pathway | Q44905699 | ||
| Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore. | Q45951244 | ||
| Covalent structure of botulinum neurotoxin type A: location of sulfhydryl groups, and disulfide bridges and identification of C-termini of light and heavy chains | Q46155602 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | intoxication | Q18621601 |
| P304 | page(s) | 202-220 | |
| P577 | publication date | 2010-12-30 | |
| P1433 | published in | Molecules | Q151332 |
| P1476 | title | Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication | |
| P478 | volume | 16 |
| Q38224215 | Botulinum neurotoxins: genetic, structural and mechanistic insights. |
| Q26764765 | Botulinum toxin A for the Treatment of Overactive Bladder |
| Q39167871 | Challenges in searching for therapeutics against Botulinum Neurotoxins |
| Q42593276 | Endomicroscopy and electromyography of neuromuscular junctions in situ |
| Q35087273 | Enhancing the Pharmacokinetic Properties of Botulinum Neurotoxin Serotype A Protease Inhibitors Through Rational Design |
| Q27675949 | Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: Synthesis, crystallography, modeling, kinetic and cellular based studies |
| Q38236640 | New targets in the search for preventive and therapeutic agents for botulism. |
| Q28548051 | Phosphatase Inhibitors Function as Novel, Broad Spectrum Botulinum Neurotoxin Antagonists in Mouse and Human Embryonic Stem Cell-Derived Motor Neuron-Based Assays |
| Q35684016 | SRC family kinase inhibitors antagonize the toxicity of multiple serotypes of botulinum neurotoxin in human embryonic stem cell-derived motor neurons |
| Q88081016 | Stem cell derived phenotypic human neuromuscular junction model for dose response evaluation of therapeutics |
| Q27671266 | Structural Framework for Covalent Inhibition of Clostridium botulinum Neurotoxin A by Targeting Cys165 |
| Q37432753 | Targeting botulinum A cellular toxicity: a prodrug approach |
| Q35992376 | The synthesis of 2,5-bis(4-amidinophenyl)thiophene derivatives providing submicromolar-range inhibition of the botulinum neurotoxin serotype A metalloprotease |
| Q34313523 | The thioredoxin reductase-thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals. |
| Q34074218 | Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors |
| Q30829084 | Ultrasound-guided botulinum toxin A injection in the treatment of belly dancer's dyskinesia |
Search more.